Successful treatment with tandem consolidation using 90 yttriumibritumomab tiuxetan (Zevalin) and high-dose therapy with autologous PBSCT in a patient with relapsed mantle cell lymphoma presenting as multiple lymphomatous polyposis
Mantle cell lymphoma (MCL) is a relatively uncommon type of non-Hodgkin's lymphoma, accounting for 2.5-10% of all non-Hodgkin's lymphoma series. Most MCL cases are diagnosed in advanced Ann Arbor stage, and extranodal involvement is common. The most common extranodal site is the BM, followed by the gastrointestinal (GI) tract. 1, 2 Remote studies reported that GI involvement occurred in about 10-30% of MCL cases, and that multiple lymphomatous polyposis was a rare form of GI involvement. However, the actual frequency may be higher than previously reported, because endoscopy is usually performed only in patients with GI symptoms. Jorge et al. reported that GI involvement was noted in most patients with MCL. 3, 4 MCL has a clinically aggressive course and a high relapse rate with a short median survival time of only 3-5 years. 5 Thus, aggressive treatment using high-dose therapy followed by autologous SCT is recommended front-line therapy. Conventional chemotherapy is considered to be a poor candidate for aggressive treatment, and it has almost lost its role in the long-term control of MCL. No current treatment can definitively cure relapsed MCL cases. Various therapeutic options, such as immunochemotherapy, allotransplantation, radioimmunotherapy (RIT), rituximab maintenance or molecular approaches, have been attempted as second-line therapy, and the search for new therapeutic drugs is ongoing. iodine-tositumomab (Bexxar; Corixa, Seattle, WA, USA). 7, 8 Because relapsed MCL is disseminated in most patients, RIT may be considered to be an attractive approach as systemic radiation therapy. A recent study reported that 90 Y-IT showed promising activity as a single agent in relapsed MCL. 9 Here, we report a case of relapsed MCL presenting as multiple lymphomatous polyposis that was successfully treated with tandem consolidation using 90 Y-IT, followed by high-dose therapy with autologous PBSCT.
A 64-year-old man was admitted with diffuse abdominal pain and hematochezia in July 2006. The patient had previously been diagnosed with mantle cell lymphoma that was histologically confirmed by a mediastinal mass in January 2005. The initial Ann Arbor stage was IIIA, including involvement of mediastinal and intra-abdominal lymph nodes. The BM biopsy result was negative. The patient received six cycles of combined chemotherapy with CHOP, and restaging subsequently confirmed CR.
In this admission, physical examination and initial laboratory studies were unremarkable: the serum level of lactate dehydrogenase was within the normal limit and no hepatic dysfunction was detected. The colonoscopic finding showed numerous polypoid lesions along the entire colon, including the ileocecal region and rectum (Figure 1 ). Histology by multiple biopsies revealed diffuse infiltration of MCL, and immunohistochemistry was positive for CD5, CD20 and cyclin D1. Cytogenetic studies revealed no abnormality. Multiple mediastinal and intra-abdominal node involvement was further identified in imaging studies using whole-body computed tomography and positron emission tomography/computed tomography scans (Figure 1) , whereas a BM biopsy was negative. According to the Ann Arbor classification, relapsed lymphoma is considered to be stage III.
The patient was treated with three courses of salvage chemotherapy using etoposide (100 mg/m 2 ; D1 to D3), ifosfamide (5 g/m 2 ; D1) and carboplatin (AUC 5; D1). Subsequently, partial regression was confirmed by colonoscopy and imaging studies (Figure 2 ). Stem cells were mobilized and collected for autologous PBSCT. After sufficient hematologic recovery, the first consolidation with 6 mobilized PBPC/kg was then infused on day 0. The patient tolerated the procedure well and has remained in CR thereafter.
To our knowledge, few reports have described the use of RIT in relapsed MCL cases. In particular, this is the first report to show successful treatment with tandem consolidation using 90 Y-IT, followed by high-dose therapy with autologous PBSCT in a patient with relapsed MCL presenting as multiple lymphomatous polyposis. Although further evaluation is necessary, RIT is considered to be an effective therapeutic option for relapsed MCL. 
